NNC45-0781

NNC45-0781 is a tissue-selective estrogen partial-agonist.

Signaling Pathways >> Others >> Estrogen Receptor/ERR

Research Areas >> Metabolic Disease

Estrogen Receptor[1]

NNC45-0781 (NNC 45-0781) shows that it is a very promising tissue-selective estrogen agonist. Total serum cholesterol is significantly increased in the vehicle-treated group as compared to the sham animals. All of the animals receiving NNC45-0781 at doses of 10 nmol/g or higher, has significantly lower levels of total serum cholesterol as compared to the vehicle treated group[1].

Rats[1] Female Sprague-Dawley rats, 12 weeks of age, weighing approximately 250 g are used in these studies.The pharmacological properties of NNC45-0781 (NNC 45-0781) are studied through a series of in vivo experiments. Activity of orally administered NNC45-0781 (1,10, 50 and 100 nmol/g) on total serum cholesterol in the ovariectomized rat.

[1]. Bury PS, et al. Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg Med Chem. 2002 Jan;10(1):125-45.

Elacestrant dihydrochloride | AZD9496 | Kaempferol | XCT 790 | Estrone | GDC-0810 | (20S)-Protopanaxatriol | 27-Hydroxycholesterol | Diethylstilbestrol | PHTPP | 2,3-bis(4-hydroxyphenyl)propionitrile | 4',7-Isoflavandiol | cholesterol | Chrysin | Endoxifen (Z-isomer hydrochloride)